Public benefit corporation United Therapeutics Corporation (Nasdaq: UTHR) and its subsidiary Lung Bioengineering Inc (LBE) announced on Wednesday that they have achieved a significant milestone, completing the 500th lung transplant using LBE's centralizsed ex vivo lung perfusion (EVLP) service. This achievement, marking the 500th transplant, occurred at Mayo Clinic in Jacksonville, Florida. LBE's service has assessed over 800 donated lungs since its launch in 2014.
Lungs are notoriously challenging to transplant, with only 20% of donated lungs in the US initially meeting the criteria for transplantation. EVLP technology has emerged as a crucial tool for evaluating and rehabilitating lungs outside the body, enabling transplant centers to determine if non-ideal lungs can become suitable for transplant. LBE specialists employ FDA-approved devices and proprietary software, such as OrganVue, to facilitate real-time assessments with transplant teams.
LBE operates full-service EVLP centers in Silver Spring, Maryland and Jacksonville, Florida, evaluating lungs from across North America, including distant locations like Alaska and Puerto Rico. Post-EVLP, these lungs have been transplanted at 25 centres, ranging geographically from Miami to Toronto and St. Louis.
Lung Bioengineering's centralised EVLP service is part of United Therapeutics' broader initiative to develop organ alternatives. This platform includes technologies in xenotransplantation, bio-artificial organs, regenerative medicine and 3D bioprinting. The company's subsidiary, Miromatrix, recently began a phase 1 trial for a bioengineered liver alternative, with plans to start clinical studies on xenokidneys by 2025, pending regulatory approval.
United Therapeutics continues to focus on expanding transplantable organ availability through innovative medical solutions.
ICU Medical establishes JV with Otsuka Pharmaceutical Factory
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration